CIK 0000873303 · Large accelerated filer
Sarepta Therapeutics, Inc.
Sign in to watch- Ticker
- SRPT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 930797222
- Phone
- 617-274-4000
- Business address
- 215 FIRST STREET, SUITE 415, CAMBRIDGE, MA, 02142
- Former names
- Sarepta Therapeutics, Inc., AVI BIOPHARMA INC, ANTIVIRALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-21 | Brown Ryan Edward EVP, General Counsel | Grant or award · Performance Stock Units 10b5-1 | +6,250 | 6,250 | ||
| 2024-06-21 | Brown Ryan Edward EVP, General Counsel | Option exercise · Performance Stock Units 10b5-1 | −6,250 | 0 | ||
| 2024-06-21 | Rodino-Klapac Louise Head of R&D, CSO | Option exercise | +6,250 | 74,323 | ||
| 2024-06-21 | Rodino-Klapac Louise Head of R&D, CSO | Grant or award · Performance Stock Units | +5,500 | 5,500 | ||
| 2024-06-21 | Rodino-Klapac Louise Head of R&D, CSO | Grant or award · Performance Stock Units | +6,250 | 6,250 | ||
| 2024-06-21 | Rodino-Klapac Louise Head of R&D, CSO | Option exercise · Performance Stock Units | −6,250 | 0 | ||
| 2024-06-21 | Murray Dallan Chief Customer Officer | Option exercise | +6,250 | 24,375 | ||
| 2024-06-21 | Murray Dallan Chief Customer Officer | Grant or award · Performance Stock Units | +5,500 | 5,500 | ||
| 2024-06-21 | Murray Dallan Chief Customer Officer | Grant or award · Performance Stock Units | +6,250 | 6,250 | ||
| 2024-06-21 | Murray Dallan Chief Customer Officer | Option exercise · Performance Stock Units | −6,250 | 0 | ||
| 2024-06-21 | Estepan Ian Michael Chief Financial Officer | Option exercise | +6,250 | 42,414 | ||
| 2024-06-21 | Estepan Ian Michael Chief Financial Officer | Grant or award · Performance Stock Units | +5,500 | 5,500 | ||
| 2024-06-21 | Estepan Ian Michael Chief Financial Officer | Grant or award · Performance Stock Units | +6,250 | 6,250 | ||
| 2024-06-21 | Estepan Ian Michael Chief Financial Officer | Option exercise · Performance Stock Units | −6,250 | 0 | ||
| 2024-06-21 | Arif Bilal Chief Tech Ops Officer | Option exercise 10b5-1 | +6,250 | 31,472 | ||
| 2024-06-21 | Arif Bilal Chief Tech Ops Officer | Grant or award · Performance Stock Units 10b5-1 | +6,250 | 6,250 | ||
| 2024-06-21 | Arif Bilal Chief Tech Ops Officer | Option exercise · Performance Stock Units 10b5-1 | −6,250 | 0 | ||
| 2024-05-02 | Murray Dallan Chief Customer Officer | Sale 10b5-1 | −3,635 | $140.00 | $509K | 18,125 |
| 2024-03-08 | Wigzell Hans Lennart Rudolf Director | Option exercise | +15,000 | $13.90 | $209K | 37,840 |
| 2024-03-08 | Wigzell Hans Lennart Rudolf Director | Sale | −3,155 | $123.85 | $391K | 34,685 |
Page 11 of 12 · 227 trades